Categories

Two million Phase II SBIR awarded
29 September 2021

Navega Therapeutics has been awarded a $2M Phase II SBIR grant from the National Cancer Institute
Two million Phase II SBIR awarded
Read more
Scientist Position
2 September 2021

Scientist position
Scientist position
Read more
Senior Research Associate
2 September 2021

Senior Research Associate
Senior Reasearch Associate position
Read more
Ana Moreno wins 2020 Mitchell Max Award
31 July 2020

Navega Therapeutics’ CEO Dr. Ana Moreno has been recognized with the 2020 Mitchell Max Award for Research Excellence in Pain

Ana Moreno wins 2020 Mitchell Max Award
Read more
NCATS collaboration Navega
27 May 2020

Navega Therapeutics Announces a Collaborative Research Agreement with the NIH's National Center for Advancing Translational Sciences (NCATS) as part of the HEAL Initiative
NCATS collaboration Navega
Read more
novel gene therapies for precision pain management
31 December 2019

The article "Novel gene therapies for precision pain management" has been published by Pharmafile
Novel gene therapies for precision pain management
Read more
Defense TechConnect conference in Maryland
16 October 2019

Navega's CEO, Dr. Ana Moreno, receives national STEM recognition
Short Interview in CBS8 to Dr. Ana Moreno, CEO
Read more
Grant from the HEAL Initiative
26 September 2019

Navega Therapeutics becomes a trusted partner of the HEAL Initiative to stem the opioid epidemic
Grant from the HEAL Initiative
Read more
TechConnect Defense Innovation Awardee
15 September 2019

Navega Therapeutics has been recognized as a TechConnect Defense Innovation Awardee

TechConnect Defense Innovation Awardee
Read more
Navega SBIR grant cancer pain
13 September 2019

Navega Therapeutics wins Phase I SBIR award from the National Cancer Institute to palliate cancer pain
Navega has been awarded a SBIR grant to treat cancer pain
Read more